Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PA
Palisade Bio, Inc. Common Stock
PALI
Mkt Cap
$245.0M
Volume
3.71M
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PA
PALI
PA
Palisade Bio, Inc. Common Stock
PALI
News
·
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Mkt Cap
$268.4M
Volume
3.71M
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Insider
Filings
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Palisade Bio announced that its lead program PALI-2108, an oral PDE4 inhibitor prodrug, will be featured in four presentations at UEG Week 2026 in Barcelona. The presentations will showcase Phase 1b findings in fibrostenotic Crohn's disease, early clinical activity in ulcerative colitis, favorable safety and tolerability, gut-targeted exposure, and a biomarker to predict treatment response. PALI-2108 is advancing into Phase 2 clinical development for both ulcerative colitis and Crohn's disease.
GlobeNewswire Inc. · Sep 28, 2026
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Palisade Bio announced Health Canada's clearance of its Clinical Trial Application for ASCENTRA-UC, a global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis. The clearance expands the study's geographic reach alongside prior U.S. regulatory approval. The company expects to begin patient dosing in the second half of 2026, with primary efficacy results anticipated in the second half of 2027.
GlobeNewswire Inc. · Sep 23, 2026
Palisade Bio to Participate in Upcoming Investor Conferences
Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company, announced that management will participate in three major healthcare investor conferences in September 2026: Wells Fargo Healthcare Conference (Sept 8-10), Morgan Stanley Global Healthcare Conference (Sept 14-16), and H.C. Wainwright Global Investment Conference (Sept 14-16). The company is advancing PALI-2108, a once-daily oral PDE4 inhibitor prodrug, into Phase 2 clinical trials for inflammatory bowel disease treatment.
GlobeNewswire Inc. · Sep 3, 2026
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Palisade Bio has canceled its previously adjourned special stockholders meeting due to lack of quorum and will withdraw proposals previously submitted for consideration.
GlobeNewswire Inc. · Oct 9, 2025
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Palisade Bio, a clinical-stage biopharmaceutical company, announced an equity grant of 2,600 stock options to a new employee as an inducement to employment.
GlobeNewswire Inc. · Jan 3, 2025
Palisade Bio to Participate in the Virtual Investor Closing Bell Series
Live video webcast on Wednesday, June 26th at 4:00 PM ET
GlobeNewswire Inc. · Jun 24, 2024
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics
GlobeNewswire Inc. · Jun 21, 2024
Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now
Palisade Bio (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks Investment Research · Jun 14, 2024
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure
GlobeNewswire Inc. · Jun 11, 2024
Palisade Bio to Present at the Virtual Investor Pitch Conference
Live video webcast on Monday, June 17th at 12:00 PM ET
GlobeNewswire Inc. · Jun 10, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PA
PALI
Palisade Bio, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
PALI
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PALI yet.
Related Tickers
Earnings